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A b s t r a c t
Introduction: Contrast-induced nephropathy (CIN) is a common clinical problem that is growing in importance as an increasing 
number of tests and procedures which utilize contrast media (CM) are performed.
Aim: To evaluate the efficacy of intravenous N-acetylcysteine (NAC) for prevention of CIN after diagnostic and/or interventional 
procedures requiring CM administration.
Material and methods: In a prospective, single-center, randomized, placebo-controlled trial the preventive effects of N-acetyl-
cysteine were evaluated in 222 patients undergoing elective angiography and/or angioplasty. Patients were randomly assigned to 
receive either NAC or placebo. All patients received intravenous hydration with normal saline before and after catheterization. Serum 
creatinine (SCr) and estimated glomerular filtration rate were assessed at baseline, at 48–72 h and 10–15 days after CM adminis-
tration. Contrast-induced nephropathy was defined as an increase in SCr of at least 44 μmol/l (0.5 mg/dl) or an increase of ≥ 25% 
of the baseline value 48–72 h after CM administration.
Results: Contrast-induced nephropathy occurred in 30 of 222 patients (13.5%): 9 of 108 patients in NAC (8.3%) and 21 of 114 
patients in the control group (18.4%; p = 0.0281). The multivariate Cox analysis revealed that elevated SCr at 10–15 days (HR = 2.69; 
p = 0.018) and baseline SCr level (HR = 1.009; p = 0.015) were independent prognostic variables for adverse events during follow-up.
Conclusions: Our findings suggest that intravenous NAC along with intravenous hydration may help prevent declining renal 
function after CM exposure. Elevated SCr level 10–15 days after CM administration was associated with increased risk of adverse 
events in long-term observation, while elevated SCr within 72 h was not. Measuring SCr at least 10 days after exposure to CM may 
provide a better outcome measure.
Key words: N-acetylcysteine, contrast-induced nephropathy, contrast agent, contrast-induced acute kidney injury, contrast me-
dium.
Introduction
Contrast-induced nephropathy (CIN) is a serious com-
plication of procedures requiring contrast media and is 
associated with rising costs, prolonged hospitalization, 
and increased mortality [1, 2]. It is a growing clinical is-
sue due to large quantities of contrast being used with 
rapid development of medical imaging technology and 
the rise of interventional cardiology for the treatment of 
cardiovascular and cerebrovascular diseases.
The most important contrast-induced nephropathy 
risk factors are impaired renal function, heart failure, di-
abetes mellitus, advanced age and procedure-dependent 
factors such as volume and type of contrast media (CM) 
used [3–5].
The effect of contrast media on renal function is 
complex and not fully understood. There are several pro-
posed mechanisms of the pathogenesis of CIN. The ma-
jor theories include renal vasoconstriction (mediated by 
Barbara Biernacka-Fiałkowska et al. N-acetylcysteine to prevent contrast-induced nephropathy
60 Advances in Interventional Cardiology 2018; 14, 1 (51)
alterations in nitric oxide (NO), endothelin, or adenosine) 
leading to acute tubular necrosis, and the direct cytotoxic 
effects of CM [6]. Administration of CM initially causes 
transient dilation, which can be followed by a period of 
sustained vasoconstriction that lasts for several hours, 
causing a reduction in renal blood flow. This may lead to 
impaired oxygenation to the outer medulla, resulting in 
ischemia to the proximal and distal tubules. With high 
concentrations of contrast within and surrounding renal 
tubular cells, there is direct cellular toxicity. The combina-
tion of both ischemic and chemotoxic injury to the prox-
imal tubules triggers a process called tubuloglomerular 
feedback, which signals the glomerulus to reduce filtra-
tion.
Many strategies have been investigated trying to 
prevent this complication. Some of them include hy-
dration with sodium bicarbonate [7, 8], hydration 
with 0.9% and 0.045% NaCl solution, administration 
of N-acetylcysteine [9–11], vitamin C [8], statins [12], 
hemofiltration, hemodialysis or short-term controlled 
tissue ischaemia [13], withdrawal of certain drugs such 
as metformin, angiotensin converting enzyme inhibitors 
(ACEIs), angiotensin II receptor blockers (ARB), and non-
steroidal anti-inflammatory drugs (NSAIDs). Taking into 
account the pathophysiology of CIN, the main focus is 
put on preventing hemodynamic changes by adequate 
hydration and the use of antioxidants. N-acetylcysteine 
(NAC), which is a potent antioxidant, is believed to have 
a positive impact on renal haemodynamics through the 
vasodilating effect of nitric oxide (NO) and reduction of 
direct renal oxidative injury [14]. N-acetylcysteine has 
been studied in various clinical trials without uniform 
results [8, 15]. Outcomes of several meta-analyses on 
the effectiveness of N-acetylcysteine are also inconsis-
tent [16–18].
In this study we aimed to assess whether adminis-
tration of intravenous NAC prior to and after contrast 
administration in well-hydrated patients was efficient in 
reducing the incidence of contrast-induced nephropathy.
Aim
The aim of this study was to evaluate the efficacy of 
intravenous N-acetylcysteine for the prevention of CIN 
after diagnostic and/or interventional procedures requir-
ing administration of contrast agent.
Material and methods
This randomized controlled trial was a single-center 
study on angiography and/or angioplasty patients, who 
were randomized to single-blind treatment with intra-
venous N-acetylcysteine or placebo, with parallel design 
and an allocation ratio of 1 : 1. The study has been ac-
cepted by local Ethic Committee of  Jagiellonian Univer-
sity Medical College. All patients gave written, informed 
consent. 
Patient population and randomization
We studied prospectively 222 patients with normal 
and impaired renal function referred to our institution 
to undergo elective coronary and/or peripheral angiog-
raphy and/or angioplasty. Patients were considered eligi-
ble for enrolment if they were over 18 years of age with 
stable creatinine levels in the last 3 months with serum 
creatinine (SCr) < 400 μmol/l and estimated glomerular 
filtration rate (eGFR) > 10 ml/min/1.72 m² (if non-dia-
betic) and > 15 ml/min/1.72 m² (if diabetic) and LVEF 
> 20%. Exclusion criteria were: haemodynamic insta-
bility (systolic blood pressure ≤ 90 mm Hg or diastolic 
≤ 50 mm Hg); acute coronary syndrome; NYHA functional 
class IV; dialysis; percutaneous renal artery angioplasty 
procedure, active gastric or duodenal ulcer, exacerbat-
ed asthma; known sensitivity to NAC and/or to contrast 
agents and inability to provide written informed consent. 
Additional exclusion criteria during the study included 
cardiogenic shock, pulmonary edema, and active gastro-
intestinal bleeding. Diagnosis and staging of impaired re-
nal function was based on K/DIGO clinical practice guide-
lines for chronic kidney disease. None of the patients 
received theophylline, dopamine, or NSAIDs during the 
study. Metformin and ACEIs were withheld 1 day before 
the contrast administration and reinstituted 2 days after 
the procedure.
Patients were randomly assigned to receive either 
antioxidant N-acetylcysteine or placebo. Randomization 
was performed based on computer generated tables. 
One hundred and eight patients were randomized to the 
NAC group and 114 patients to the placebo group. One 
patient did not receive the full allocated intervention. Ten 
patients were lost to long-term follow-up due to inability 
to contact the person or withdrawal of consent (6 partic-
ipants from the NAC group and 4 participants from the 
placebo group). For details check the Consort Diagram 
(Figure 1) [19, 20].
Procedural protocol and follow-up
Both groups received intravenous hydration with 
0.9% saline before and after administration of the con-
trast agent. N-acetylcysteine was given intravenously at 
a  dose of 600 mg, diluted in 100 ml of 0.9% NaCl, on 
the day before the procedure (about 12 h before), on the 
day of administration of the CM twice daily, and on the 
day after administration of the contrast agent twice daily 
(5 doses, of which 2 were given before and 3 were giv-
en after exposure to CM). Patients in the placebo group 
received 100 ml of 0.9% NaCl solution. Patients did not 
know whether N-acetylcysteine was diluted in 100 ml of 
0.9% NaCl or whether they received 0.9% NaCl solution 
alone. Physicians and nurses however were not blinded 
(single-blinded study). Hydration with 0.9% NaCl solution 
– the same in both groups – was given intravenously at 
a rate of 1–1.5 ml/kg body weight per hour for 12 h be-
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fore and 12 h after administration of the contrast agent. 
Patients were not allowed to drink extra fluids for 12 h 
before and after the procedure, after which there were 
no oral fluid restrictions. All patients received a nonionic 
contrast agent (one of the following: iomeprol, iohexol, 
iopromide, iodixanol). The dose of contrast agent was 
left to the discretion of the attending cardiologist.
Serum creatinine level was measured immediately be-
fore, 48–72 h after administration of the contrast agent 
and 10–15 days after exposure to CM. In all patients esti-
mated glomerular filtration rate (eGFR) was calculated by 
applying the mdification of diet in renal disease (MDRD) 
formula to the baseline serum creatinine level: eGFR [ml/
min/1.72 m²] = 186 × SCr–1.154 × age [years]–0.203 × (0.743 
if female) × 1.210, where: eGFR – estimated glomerular 
filtration rate, SCr – serum creatinine level [μmol/l].
Contrast-induced nephropathy was defined as an in-
crease in the serum creatinine concentration of at least 
44 μmol/l (0.5 mg/dl) or an increase in the serum creati-
nine concentration of at least 25% of the baseline value 
at 48–72 h after administration of contrast agent [6].
Patients underwent long-term clinical follow-up includ-
ing occurrence of major adverse cardiac events (MACE) 
such as cardiovascular death, heart infarct, as well as di-
alysis and recurrent hospitalization (due to cardiac or re-
nal causes). The first follow-up visit was performed 10–15 
days after CM exposure and included history taking and 
physical examination. Blood was also drawn to measure 
the serum creatinine level. The second follow-up contact 
was obtained at least 6 months after CM exposure via 
telephone, at the end of the study. If an adverse event 
occurred the patient was asked to attend a clinical visit, 
where medical records were analyzed and again history 
was taken and physical examination performed.
Statistical analysis
Results are presented as mean SD or a percentage of 
the total. Continuous data were compared by means of 
Student’s t test. Categorical variables were analyzed by 
Fisher’s exact test and the c2 test. Differences between 
the groups in creatinine concentration were analyzed 
by the nonparametric Mann-Whitney test. Non-paired 
variables were analyzed by the unpaired t test. A p-value 
0.05 was considered statistically significant. 
Overall survival was calculated using the Kaplan-Mei-
er method. Independent variables were first analyzed 
Figure 1. Consort flow diagram
Assessed for eligibility (N = 294)
Excluded (n = 67)
Not meeting inclusion criteria (n = 18)
Declined to participate (n = 48)
Other reason (n = 1, qualification to procedure has changed) 
Allocated to intervention (n = 111)
Received allocated intervention (n = 110)
Did no receive allocated intervention (n = 1, allergic reaction)
Lost to follow-up (n = 1, failure to assess all required  
creatinine measurements  
n = 1 did not attend scheduled follow-up visit)
Analysed (n = 108)
Excluded from analysis (n = 3, not final survey)
Long term follow-up (n = 102)
Excluded from analysis (n = 6, withdrawal of consent  
or inability to contact the person)
Allocated to placebo (n = 116)
Received allocated intervention (n = 116) 
Lost to follow-up (n = 2, failure to assess  
all required creatinine measurements)
Analysed (n = 114)
Excluded from analysis (n = 2, not final survey)
Long term follow-up (n = 110)
Excluded from analysis (n = 4, withdrawal of consent  
or inability to contact the person)
Randomised (N = 227) 
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with univariate analysis. Variables with p < 0.10 in the 
univariate model were entered into a  Cox proportional 
hazards regression model for multivariate analysis. Sta-
tistical significance was defined as p < 0.05. 
Data were analyzed using SPSS 24.0 for Windows 




The clinical and biochemical characteristics of the pa-
tients in the two groups are shown in Table I. 
Among 222 patients, 210 underwent a  diagnostic 
procedure (coronary angiography or peripheral artery an-
giography), with an eventual (ad-hoc) therapeutic proce-
dure in 111 of the patients (percutaneous coronary inter-
vention (PCI) or percutaneous transluminal angioplasty 
(PTA) of a peripheral artery). Twelve patients underwent 
elective PCI or PTA.
The amount of contrast agent administered was sim-
ilar between the two groups (196.7 ±85.9 ml in the NAC 
group vs. 204.0 ±84.2 ml in the placebo group; p = NS). 
There was no significant difference in the intravenous hy-
dration volume between the NAC group (993.4 ±154.1 ml) 
and the placebo group (983.8 ±146.1 ml).
None of the patients required dialysis. In 1 patient 
from the NAC group during the infusion of N-acetylcys-
teine a rash on the forearm was noted, and the infusion 
was stopped; no other systemic manifestations were 
present. No other adverse effects were observed.
Changes in renal function
The mean serum creatinine concentration for all pa-
tients was 96.4 ±39.1 μmol/l and the mean eGFR (us-






Age 66.0 ±8.9 64.3 ±9.5 NS
Male, n (%) 88 (81.5) 83 (72.8) NS
Hypertension, n (%) 98 (90.7) 103 (90.4) NS
DM, n (%) 34 (31.5) 36 (31.6) NS
CAD, n (%) 71 (65.7) 81 (71.1) NS
PAD, n (%) 33 (30.6) 25 (21.9) NS
VHD, n (%) 4 (3.7) 8 (7.0) NS
Prior MI, n (%) 38 (35.2) 40 (35.1) NS
Prior stroke, n (%) 20 (18.5) 16 (14.0) NS
RBC [× 106/mm3] 4.8 ±0.5 4.7 ±0.5 NS
HGL [g/dl] 14.5 ±1.4 14.3 ±1.4 NS
HCT (%) 42.4 ±3.8 41.8 ±3.8 NS
SCr [μmol/l] 98.5 ±42.0 94.3 ±36.3 NS
eGFR [ml/min/1.72 m²] 76.2 ±24.5 77.2 ±27.2 NS
ACR [mg/g] 40.4 ±111.1 38.2 ±101.9 NS
LVEF (%) 58.4 (9.6) 56.2 (10.9) NS
NYHA class, n (%):
I 18 (16.7) 18 (15.8) NS 
II 71 (65.7) 75 (65.8) NS
III 19 (17.6) 21 (18.4) NS
IV (exclusion criteria) 0 (0.0) 0 (0.0)
BMI [kg/m2] 27.8 ±3.6 28.3 ±4.1 NS
Total contrast volume [ml] 196.7 ±85.9 204.0 ±84.2 NS
Intravenous hydration volume [ml] 993.4 ±154.1 983.8 ±146.1 NS
DM – diabetes mellitus, CAD – coronary artery disease, PAD – peripheral artery disease, VHD – valvular heart disease, ACR – urine albumin/creatinine ratio, LVEF – left 
ventricular ejection fraction, BMI – body mass index.
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ing MDRD formula) was 76.7 ±25.9 ml/min/1.72 m². In 
the N-acetylcysteine group, the mean serum creatinine 
concentration increased from 98.5 ±42.0 to 103.9 ±46.7 
μmol/l 48–72 h after administration of the contrast 
agent and eGFR decreased from 76.2 ±24.5 to 72.6 ±23.9 
ml/min/1.72 m². In the placebo group, the mean serum 
creatinine concentration increased from 94.3 ±36.3 to 
105.7 ±48.0 μmol/l 48–72 h after administration of the 
contrast agent and eGFR decreased from 77.2 ±27.2 to 
69.7 ±25.6 ml/min/1.72 m². The absolute change in se-
rum creatinine concentration was significantly greater 
in the placebo group than in the N-acetylcysteine group 
(11.4 ±21.7 vs. 5.4 ±15.1 μmol/l; p < 0.05). Likewise, the 
absolute change in eGFR was significantly greater in the 
control group as compared to the NAC group (7.5 ±11.9 
vs. 3.6 ±11.8 μmol/l; p < 0.05).
Contrast-induced nephropathy occurred in 30 of the 
222 (13.5%) patients: 9 of the 108 patients in the N-ace-
tylcysteine group (8.3%) and 21 of the 114 patients in 
the control group (18.4%; p < 0.05). 
During hospitalization there were no heart infarcts, 
no need of dialysis and no cardiovascular deaths. Mean 
hospitalization time in patients with CIN was significant-
ly longer than in patients without CIN (5.9 ±3.2 days vs. 
4.9 ±2.0 days; p < 0.05). 
At the 6-month follow-up (542 ±222 days) among 
212 patients there were 6 deaths (2 of them were cardio-
vascular deaths), 5 heart infarcts and 1 dialysis. Thirty-six 
patients required at least 1 recurrent hospitalization due 
to cardiac causes and 5 patients required at least 1 recur-
rent hospitalization due to renal causes (Table II).
In long-term follow-up probability of adverse event-
free survival was significantly greater in patients without 
elevated creatinine levels (defined as an increase in SCr 
of at least 44 μmol/l (0.5 mg/dl) or an increase of ≥ 25% 
of the SCr baseline value) 10–15 days after CM admin-
Table II. Adverse events at 6-month follow-up





Death (all causes): 2 (1.8%) 4 (3.9%) NS
CV 1 (0.9%) 1 (0.9%) NS
Other 1 (0.9%) 3 (2.6%) NS
MI 2 (1.8%) 3 (2.6%) NS
Dialysis 1 (0.9%) 0 (0%) NS
Rehospitalization (cardiac causes) 20 (18.1%) 16 (15.7%) NS
Rehospitalization (renal causes) 3 (2.7%) 2 (2.0%) NS
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Log rank p = 0.03
Elevated serum creatinine levels 10–15 days  
after contrast administration
 Yes          No
Figure 2. Kaplan-Meier adverse event free survival 
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Figure 3. Kaplan-Meier adverse event free survival 
in patients with CIN
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Table III. Multivariate Cox regression model of predictors associated with long-term mortality
Variables HR –95% CI +95% CI P-value
Age 1.027985 0.006404 0.061606 0.111638
Baseline SCr 1.008612 0.003183 0.016278 0.015249
Elevated SCr after 10–15 days 2.692329 0.168428 1.812385 0.018198
LVEF 0.975952 0.002435 0.051119 0.074793
SCr – serum creatinine concentration, LVEF – left ventricular ejection fraction.
istration, as compared to those with elevated creatinine 
levels (Figure 2). Probability of adverse event-free surviv-
al in patients with CIN after 48–72 h did not differ signifi-
cantly from the patients without CIN (Figure 3). 
Univariate analysis showed that age (p = 0.028), el-
evated baseline serum creatinine level (p = 0.002), left 
ventricle ejection fraction (LVEF) (p = 0.021) and elevated 
serum creatinine level at 10–15 days after CM adminis-
tration meeting criteria described above (p = 0.035) were 
significantly associated with increased risk of adverse 
events including death, myocardial infarction, dialysis, 
and rehospitalization due to renal or cardiac causes.
The multivariate Cox analysis revealed that elevat-
ed baseline serum creatinine level (HR = 1.009, 95% CI: 
1.003–1.016,  p = 0.015), and elevated serum creati-
nine level at 10–15 days  (HR = 2.69, 95% CI: 0.168–
1.812, p = 0.018) remained independent prognostic vari-
ables for adverse events during follow-up (Table III).
Discussion
Many interventions to reduce the risk of CIN have 
been studied, but to date, the evidence has been incon-
clusive. 
In our study the use of intravenous N-acetylcysteine 
and hydration with 0.9% saline reduced the incidence of 
CIN in patients receiving intra-arterial contrast media as 
compared with standard hydration alone. 
Tepel et al. were the first to evaluate the role of pre-
venting CIN in patients with impaired renal function with 
antioxidant N-acetylcysteine [9]. Patients undergoing 
computed tomography were randomly treated with hy-
dration plus placebo or hydration plus N-acetylcysteine 
(600 mg orally twice daily) before and after adminis-
tration of the contrast agent. A difference between our 
study and that of Tepel was in the protocol for N-acetyl-
cysteine administration. Tepel et al. [9] gave the drug at 
600 mg orally twice daily, the day before and on the day 
of contrast infusion, while in our study protocol the drug 
was applied at the same dosage but intravenously and 
for 3 days rather than 2 days (the day before, on the day 
of contrast infusion and on the day after the procedure). 
We used intravenous N-acetylcysteine because of a high 
first-pass effect, resulting in very low bioavailability of 
< 10% after oral administration [21]. 
Some authors have shown a dose-dependent effect 
of intravenous N-acetylcysteine for the prevention of 
contrast-induced nephropathy in patients receiving con-
trast media [10, 22].
However, other trials showed lack of benefit of N-ace-
tylcysteine in the prevention of contrast-induced ne-
phropathy [23]. 
The largest randomized controlled trial to date, the 
Acetylcysteine for Contrast-induced nephropathy Trial 
(ACT) [11], found neutral effects of N-acetylcysteine for 
the prevention of contrast-induced acute kidney injury. 
However, there are some important differences between 
this and our study that are worth noting. First of all, in 
the ACT study patients were administered 0.9% NaCl, 
1 ml/kg/h for 6 h before and after the procedure, where-
as in our study it was 1–1.5 ml/kg for 12 h before and 
after contrast administration. That is a slight difference. 
Volume and timing and route of hydration may be im-
portant. Some studies have demonstrated that the adop-
tion of hydration may influence efficacy of NAC in pre-
venting CIN [18]. Secondly, the mean volume of contrast 
medium administered in the ACT trial was significantly 
smaller (circa 100 ml), while in our study it was 200 
±85.0 ml. Thirdly, N-acetylcysteine in the ACT trial was 
administered orally, while in our study NAC was given 
intravenously. Taking into consideration the low bioavail-
ability of oral NAC due to first-pass hepatic metabolism, 
this might have also contributed to the different results 
of our study and the ACT trial as only a small proportion 
of the administered dose is available for renal protection.
The results of our study are consistent with recent 
meta-analyses, which supported the use of NAC in the 
prevention of CIN in patients exposed to contrast me-
dia [16–18] (although the strength of evidence favoring 
the use of low-dose NAC was low). That may explain why 
low-dose NAC is not used more often and helps to explain 
differing recommendations on its use to prevent CIN. 
The 2014 ESC/EACTS Guidelines on myocardial re-
vascularization recommend against the use of NAC for 
patients receiving intra-arterial contrast media in cardiac 
procedures [24], whereas the 2012 Kidney Disease: Im-
proving Global Outcomes Clinical Practice Guideline for 
Acute Kidney Injury suggests using oral N-acetylcysteine 
with intravenous fluids in patients with increased CIN 
risk, acknowledging low strength of evidence [25].
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To conclude, research on intravenous N-acetylcyste-
ine and the incidence of CIN is very inconsistent. It is dif-
ficult to warrant a definite conclusion at present on the 
efficacy of NAC. 
A large, well-designed trial that incorporates the eval-
uation of clinically relevant outcomes in participants with 
different underlying risks of CIN is required to more ad-
equately assess the role for intravenous NAC in CIN pre-
vention.
Taking into consideration the pathomechanism of 
CIN development, perhaps there are some factors that 
influence the efficacy of CIN, such as insufficient hydra-
tion in trials failing to show NAC usefulness.
Contrast-induced nephropathy is associated with 
significantly increased in-hospital morbidity, mortality, 
and costs. It is believed that CIN occurring within 72 h 
after administration of CM is associated with increased 
in-hospital and long-term mortality [26]. 
In our study there were no in-hospital deaths and no 
need for dialysis during hospitalization, but mean hospi-
talization time in patients with CIN was significantly lon-
ger than in patients without CIN, which is consistent with 
some other studies [26]. In our study we found that ele-
vated creatinine level 10–15 days after contrast admin-
istration was associated with increased risk of adverse 
events in long-term follow-up. Interestingly, there was 
no such association with CIN occurring within 72 h after 
CM exposure in our study. Similar findings were reported 
by Holscher et al. [27]. In a  study reported by Holscher 
et al. [27] elevated creatinine levels at 30 days after cath-
eterization, but not within 72 h, had a significant effect 
on the long-term outcome of the patients. Taking into 
consideration the pathophysiology of acute kidney injury 
caused by contrast media and the fact that recovery and 
regeneration of tubular cells from within the tubule struc-
ture may take 8 to 10 days [28], assessing kidney function 
within 72 h may be too early, as the process of renal func-
tion recovery may take longer. In healthy subjects there is 
a great tubular repair capability and exposure to contrast 
media may have no significant clinical consequences [29]. 
However, patients with CKD and diabetes mellitus may 
develop clinically important CIN more easily, as they have 
a reduced number of functioning nephrons and impaired 
ability to regenerate tubular epithelial cells. Some of the 
nephrons may thus never fully recover, leading to loss of 
the functional unit and finally fibrosis [28]. In study re-
ported by Abaci et al. [30], exposure to CM was an in-
dependent predictor of the composite outcome measure 
of death or renal failure requiring dialysis in 3-year long-
term observation. Interestingly, exposure to CM was an 
independent predictor of long-term adverse events, even 
when if it did not cause acute kidney injury (creatinine 
was measured 48–96 h after administration of CM). 
So far this subject has not been extensively inves-
tigated. A  large, well-designed trial is required to give 
more insight into this topic. 
Conclusions
In our study intravenous administration of N-acetyl-
cysteine at a dose of 600 mg and hydration with 0.9% 
NaCl saline solution reduced the incidence of contrast-in-
duced nephropathy in patients undergoing cardiac or 
peripheral angiography and/or angioplasty. The investi-
gated strategy was also safe and inexpensive. Elevated 
creatinine level 10–15 days after contrast administration 
was associated with increased risk of adverse events in 
long-term observation, while elevated creatinine level 
within 72 h was not. Measuring creatinine level at least 
10 days after exposure to contrast media may provide 
a better outcome measure.
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